0000899243-19-003492.txt : 20190213 0000899243-19-003492.hdr.sgml : 20190213 20190213182556 ACCESSION NUMBER: 0000899243-19-003492 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190213 FILED AS OF DATE: 20190213 DATE AS OF CHANGE: 20190213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Menzel Garry E CENTRAL INDEX KEY: 0001556064 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38811 FILM NUMBER: 19599461 MAIL ADDRESS: STREET 1: C/O REGULUS THERAPEUTICS INC. STREET 2: 3545 JOHN HOPKINS COURT SUITE 210 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC. CENTRAL INDEX KEY: 0001750019 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 474152751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-949-5200 MAIL ADDRESS: STREET 1: 100 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-02-13 0 0001750019 TCR2 THERAPEUTICS INC. TCRR 0001556064 Menzel Garry E TCR2 THERAPEUTICS INC. 100 BINNEY STREET CAMBRIDGE MA 02142 1 1 0 0 President & CEO Common Stock 84527 I See Footnote Stock Option (Right to Buy) 0.74 2026-12-12 Common Stock 253581 D Stock Option (Right to Buy) 0.74 2027-12-06 Common Stock 143977 D Stock Option (Right to Buy) 5.88 2028-07-25 Common Stock 433037 D Consists of 84,527 shares of common stock held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities. The Reporting Person was granted an option to purchase 253,581 shares on December 13, 2016. 84,527 of such options were previously exercised. 25% of this option vested and became exercisable on October 17, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. 25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. 25% of this option shall vest and become exercisable on July 26, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Exhibit 24.1: Power of Attorney /s/ Garry E. Menzel 2019-02-13 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                               Power of Attorney

   Know all by these presents, that the undersigned hereby constitutes and
appoints each of Margaret Siegel and Stephen Turkowiak, signing singly, and with
full power of substitution, as the undersigned's true and lawful attorney-in-
fact to:

     (1) execute for and on behalf of the undersigned, in the undersigned's
     capacity as an officer and/or director of TCR2 Therapeutics Inc., a
     Delaware corporation (the "Company"), from time to time the following
     Securities and Exchange Commission (the "SEC") forms: Forms 3, 4, and 5 in
     accordance with Section 16(a) of the Securities Exchange Act of 1934, as
     amended (the "Exchange Act"), and the rules thereunder;

     (2) do and perform any and all acts for and on behalf of the undersigned
     which may be necessary or desirable to complete and execute any such Form
     3, 4, or 5, complete and execute any amendment or amendments thereto, and
     timely file such form with the SEC and any stock exchange or similar
     authority; and

     (3) take any other action of any type whatsoever in connection with the
     foregoing which, in the opinion of such attorney-in-fact, may be of benefit
     to, in the best interest of, or legally required by, the undersigned, it
     being understood that the documents executed by such attorney-in-fact on
     behalf of the undersigned pursuant to this Power of Attorney shall be in
     such form and shall contain such terms and conditions as such attorney-in-
     fact may approve in such attorney-in-fact's discretion.

   The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

   This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an officer of
the Company. This Power of Attorney may be filed with the SEC as a confirming
statement of the authority granted herein.

   IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 13th day of February, 2019.

              /s/ Garry E. Menzel
              -------------------
Printed Name: Garry E. Menzel